Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1524) 1524
Publication (101) 101
Newsletter (78) 78
Book Review (39) 39
Book Chapter (6) 6
Magazine Article (4) 4
Data Set (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
paroxetine (1090) 1090
humans (1017) 1017
male (748) 748
pharmacology & pharmacy (638) 638
female (592) 592
psychiatry (518) 518
adult (479) 479
fluoxetine (386) 386
index medicus (378) 378
middle aged (348) 348
antidepressants (327) 327
neurosciences (326) 326
animals (319) 319
pharmacokinetics (269) 269
serotonin (259) 259
depression (256) 256
paroxetine - pharmacokinetics (240) 240
drug interactions (234) 234
aged (229) 229
serotonin uptake inhibitors - therapeutic use (222) 222
paroxetine - pharmacology (220) 220
paroxetine - therapeutic use (209) 209
sertraline (207) 207
serotonin uptake inhibitors - pharmacology (201) 201
serotonin reuptake inhibitors (199) 199
rats (193) 193
serotonin uptake inhibitors - pharmacokinetics (189) 189
clinical neurology (182) 182
double-blind (179) 179
depressive disorder - drug therapy (175) 175
serotonin uptake inhibitors - adverse effects (174) 174
dose-response relationship, drug (166) 166
paroxetine - adverse effects (164) 164
fluvoxamine (161) 161
adolescent (145) 145
major depression (145) 145
treatment outcome (138) 138
citalopram (135) 135
metabolism (131) 131
drugs (126) 126
efficacy (126) 126
antidepressive agents - therapeutic use (122) 122
research (120) 120
double-blind method (119) 119
paroxetine - administration & dosage (114) 114
pharmacology (113) 113
brain - metabolism (112) 112
depressive disorder, major - drug therapy (112) 112
paroxetine - blood (107) 107
serotonin uptake inhibitors (107) 107
major depressive disorder (106) 106
serotonin - metabolism (104) 104
analysis (98) 98
serotonin transporter (94) 94
serotonin uptake inhibitors - administration & dosage (93) 93
drug therapy (91) 91
depression, mental (90) 90
antidepressive agents, second-generation - therapeutic use (89) 89
in-vitro (89) 89
cytochrome p-450 (88) 88
antidepressant (87) 87
serotonin plasma membrane transport proteins (87) 87
brain (86) 86
cyp2d6 (85) 85
rats, sprague-dawley (84) 84
venlafaxine (84) 84
antidepressive agents - pharmacology (82) 82
drug therapy, combination (81) 81
time factors (81) 81
antidepressive agents - adverse effects (78) 78
antidepressive agents - pharmacokinetics (78) 78
antidepressive agents, second-generation - adverse effects (77) 77
brain - drug effects (77) 77
h-3 paroxetine binding (77) 77
psychiatric status rating scales (75) 75
cytochrome p-450 cyp2d6 - metabolism (74) 74
depression - drug therapy (73) 73
young adult (73) 73
membrane transport proteins (72) 72
pharmacology/toxicology (72) 72
placebo (71) 71
blood platelets - metabolism (70) 70
health aspects (70) 70
mice (70) 70
depressive disorder - psychology (69) 69
fluoxetine - pharmacology (69) 69
care and treatment (68) 68
medicine & public health (68) 68
nerve tissue proteins (68) 68
serotonin uptake inhibitors - blood (68) 68
antidepressive agents, second-generation - pharmacokinetics (66) 66
cytochrome p-450 cyp2d6 inhibitors (66) 66
genotype (66) 66
imipramine (66) 66
rat-brain (66) 66
drug administration schedule (65) 65
paroxetine - metabolism (64) 64
ssri (64) 64
area under curve (63) 63
metabolites (63) 63
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1574) 1574
German (10) 10
French (6) 6
Spanish (6) 6
Japanese (4) 4
Dutch (3) 3
Norwegian (2) 2
Chinese (1) 1
Danish (1) 1
Korean (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Influence of the cytochrome P450 2D6 10/10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis
by Nishimura, Miki and Ueda, Mikito and Saruwatari, Junji and Nakashima, Hiroo and Ogusu, Naoki and Aoki, Akiko and Tsuchimine, Shoko and Matsuda, Kazuki and Iwashita, Kazuma and Ono, Tatsumasa and Oniki, Kentaro and Shimoda, Kazutaka and Yasui-Furukori, Norio
Pharmacogenetics and Genomics, ISSN 1744-6872, 09/2016, Volume 26, Issue 9, pp. 403 - 413
OBJECTIVEAlthough the reduced function of the cytochrome P450 2D6*10 (CYP2D6*10) allele is common among Asian populations, existing evidence does not support... 
paroxetine | CYP2D6 | polymorphisms | dose requirement | population pharmacokinetics | Paroxetine - pharmacokinetics | Cytochrome P-450 CYP2D6 - genetics | Serotonin Uptake Inhibitors - pharmacokinetics | Gene Frequency | Humans | Japan | Middle Aged | Asian Continental Ancestry Group - genetics | Male | Paroxetine - administration & dosage | Young Adult | Serotonin Uptake Inhibitors - administration & dosage | Depressive Disorder, Major - genetics | Adolescent | Pharmacogenomic Variants | Adult | Female | Aged | Polymorphism, Single Nucleotide | Retrospective Studies | Depressive Disorder, Major - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Selective serotonin reuptake inhibitors (SSRIs): Therapeutic drug monitoring and pharmacological interactions
by Mandrioli, R and Mercolini, L and Saracino, M.A and Raggi, M.A
Current Medicinal Chemistry, ISSN 0929-8673, 04/2012, Volume 19, Issue 12, pp. 1846 - 1863
New-generation antidepressants are a heterogeneous class of drugs used in the treatment of depression and related disorders. This review deals with the first... 
Paroxetine | Antidepressants | Fluoxetine | Pharmacological properties | Selective serotonin reuptake inhibitors (SSRIs) | Therapeutic drug monitoring (TDM) | Vilazodone | Fluvoxamine | Sertraline | Chemical-clinical correlations | Citalopram | ELECTRON-CAPTURE DETECTION | POSTTRAUMATIC-STRESS-DISORDER | CHEMISTRY, MEDICINAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | fluvoxamine | TANDEM MASS-SPECTROMETRY | pharmacological properties | OBSESSIVE-COMPULSIVE DISORDER | PERFORMANCE LIQUID-CHROMATOGRAPHY | chemical-clinical correlations | therapeutic drug monitoring (TDM) | fluoxetine | paroxetine | selective serotonin reuptake inhibitors (SSRIs) | PHARMACOLOGY & PHARMACY | MAJOR DEPRESSIVE DISORDER | PLACEBO-CONTROLLED TRIAL | NEW-GENERATION ANTIDEPRESSANTS | citalopram | TRANSPORTER BINDING PROFILE | vilazodone | sertraline | SOLID-PHASE EXTRACTION | Paroxetine - pharmacokinetics | Serotonin Uptake Inhibitors - pharmacokinetics | Fluoxetine - pharmacokinetics | Humans | Citalopram - adverse effects | Depressive Disorder - drug therapy | Paroxetine - therapeutic use | Sertraline - adverse effects | Paroxetine - adverse effects | Benzofurans - pharmacokinetics | Sertraline - pharmacokinetics | Vilazodone Hydrochloride | Sertraline - therapeutic use | Fluoxetine - therapeutic use | Piperazines - pharmacokinetics | Fluoxetine - adverse effects | Fluvoxamine - therapeutic use | Benzofurans - therapeutic use | Serotonin Uptake Inhibitors - therapeutic use | Fluvoxamine - pharmacokinetics | Serotonin Uptake Inhibitors - adverse effects | Piperazines - therapeutic use | Benzofurans - adverse effects | Depressive Disorder - metabolism | Fluvoxamine - adverse effects | Piperazines - adverse effects | Indoles - adverse effects | Citalopram - pharmacokinetics | Citalopram - therapeutic use | Indoles - pharmacokinetics | Indoles - therapeutic use | Drug Monitoring
Journal Article
Details down arrow
3. Full Text Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers
by Glue, Paul and Winter, Helen and Garbe, Kira and Jakobi, Hannah and Lyudin, Alexander and Lenagh‐Glue, Zoe and Hung, C. Tak
The Journal of Clinical Pharmacology, ISSN 0091-2700, 06/2015, Volume 55, Issue 6, pp. 680 - 687
Conversion of ibogaine to its active metabolite noribogaine appears to be mediated primarily by CYP2D6. We compared 168 hours pharmacokinetic profiles of both... 
ibogaine | paroxetine | CYP2D6 | noribogaine | pharmacodynamics | safety | pharmacokinetics | DRUG | O-DEMETHYLATION | 12-HYDROXYIBOGAMINE | SERTRALINE | FLUOXETINE | PHARMACOLOGY & PHARMACY | Paroxetine - pharmacokinetics | Cytochrome P-450 CYP2D6 Inhibitors - pharmacokinetics | Excitatory Amino Acid Antagonists - pharmacokinetics | Humans | Ibogaine - pharmacokinetics | Half-Life | Ibogaine - administration & dosage | Male | Healthy Volunteers | Ibogaine - metabolism | Dose-Response Relationship, Drug | Paroxetine - administration & dosage | Young Adult | Drug Interactions | Time Factors | Ibogaine - analogs & derivatives | Cytochrome P-450 CYP2D6 - metabolism | Adult | Female | Ibogaine - analysis | Physiological aspects | Paroxetine | Dosage and administration | Ibogaine | Observations | Drug interactions
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
by Stearns, Vered and Johnson, Michael D and Rae, James and Morocho, Alan and Novielli, Antonella and Bhargava, Pankaj and Hayes, Daniel F and Desta, Zeruesenay and Flockhart, David A
Journal of the National Cancer Institute, ISSN 0027-8874, 12/2003, Volume 95, Issue 23, pp. 1758 - 1764
Background: Tamoxifen, a selective estrogen receptor modulator (SERM), is converted to 4-hydroxy-tamoxifen and other active metabolites by cytochrome P450... 
PERFORMANCE LIQUID-CHROMATOGRAPHY | BREAST-CANCER | MAJOR METABOLITES | ONCOLOGY | 4-HYDROXYLATION | RANDOMIZED CONTROLLED-TRIAL | HUMAN LIVER-MICROSOMES | CYP2D6 ACTIVITY | HOT FLASHES | CYTOCHROME-P450 2D6 | VENLAFAXINE | Cytochrome P-450 CYP2D6 Inhibitors | Paroxetine - pharmacokinetics | Serotonin Uptake Inhibitors - pharmacokinetics | Prospective Studies | Cytochrome P-450 Enzyme Inhibitors | Selective Estrogen Receptor Modulators - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - blood | Cytochrome P-450 CYP3A | Humans | Microsomes, Liver - metabolism | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Tamoxifen - administration & dosage | Antineoplastic Agents, Hormonal - pharmacokinetics | Paroxetine - administration & dosage | Paroxetine - blood | Breast Neoplasms - enzymology | Adult | Female | Serotonin Uptake Inhibitors - blood | Chemotherapy, Adjuvant | Antineoplastic Agents, Hormonal - administration & dosage | Enzyme Inhibitors - pharmacology | Tamoxifen - blood | Selective Estrogen Receptor Modulators - administration & dosage | Treatment Outcome | Tamoxifen - pharmacokinetics | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - blood | Selective Estrogen Receptor Modulators - blood | Serotonin Uptake Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - blood | Tamoxifen - analogs & derivatives | Aged | Paroxetine | Evaluation | Serotonin uptake inhibitors | Tamoxifen
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Blood–brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls
by Uhr, Manfred and Grauer, Markus T and Yassouridis, Alexander and Ebinger, Martin
Journal of Psychiatric Research, ISSN 0022-3956, 2005, Volume 41, Issue 1, pp. 179 - 188
Abstract In earlier studies with P-gp (abcb1) knock-out mice, we showed that P-gp exports the antidepressants citalopram, paroxetine, venlafaxine and... 
Psychiatry | P-glycoprotein | Nortriptyline | Amitriptyline | abcb1 | Knock-out mice | Blood–brain barrier | Blood-brain barrier | blood-brain barrier | nortriptyline | amitriptyline | LOCALIZATION | CORTICOSTERONE | PSYCHIATRY | MOUSE | MULTIDRUG-RESISTANCE PROTEIN | DRUG TRANSPORTERS | MDR1A | ENDOTHELIAL-CELLS | GENE DISRUPTION | CENTRAL-NERVOUS-SYSTEM | knock-out mice | EXPRESSION | Antidepressive Agents, Tricyclic - pharmacokinetics | Cerebellum - metabolism | Blood-Brain Barrier - drug effects | ATP Binding Cassette Transporter, Subfamily B | Mice, Knockout | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Animals | Biological Transport | Amitriptyline - pharmacokinetics | ATP-Binding Cassette Transporters - metabolism | Female | Mice | Antidepressive Agents, Tricyclic - administration & dosage | Amitriptyline - administration & dosage | Ovary - metabolism | Paroxetine | Metabolites | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Effect of Inhibition of Cytochrome P450 Enzymes 2D6 and 3A4 on the Pharmacokinetics of Intravenous Oxycodone
: A Randomized, Three-Phase, Crossover, Placebo-Controlled Study
by Grönlund, Juha and Saari, Teijo I and Hagelberg, Nora M and Neuvonen, Pertti J and Laine, Kari and Olkkola, Klaus T
Clinical Drug Investigation, ISSN 1173-2563, 3/2011, Volume 31, Issue 3, pp. 143 - 153
Oxycodone is a μ-opioid receptor agonist that is mainly metabolized by hepatic cytochrome P450 (CYP) enzymes. Because CYP enzymes can be inhibited by other... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Paroxetine, therapeutic use | Cytochrome-P450 | Oxycodone, pharmacokinetics | Itraconazole, therapeutic use | Analgesics, pharmacokinetics | PHARMACOLOGY & PHARMACY | Cytochrome P-450 CYP2D6 Inhibitors | Oxycodone - pharmacology | Humans | Enzyme Inhibitors - pharmacology | Analgesics, Opioid - pharmacology | Half-Life | Male | Itraconazole - pharmacology | Analgesics, Opioid - classification | Cross-Over Studies | Young Adult | Oxycodone - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors | Drug Interactions | Cytochrome P-450 CYP3A - metabolism | Cytochrome P-450 CYP2D6 - metabolism | Adult | Female | Paroxetine - pharmacology | Physiological aspects | Paroxetine | Research | Pharmacokinetics | Health aspects | Cytochrome P-450
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Polymorphism in CYP2D6 affects the pharmacokinetics and dose escalation of paroxetine controlled-release tablet in healthy Chinese subjects
by Chen, Rui and Shen, Kai and Hu, Pei
International Journal of Clinical Pharmacology and Therapeutics, ISSN 0946-1965, 2017, Volume 55, Issue 11, pp. 853 - 860
This study evaluated the effects of CYP2D6 polymorphisms on the pharmacokinetics and dose escalation of controlled-release paroxetine over the dose range of... 
Paroxetine | Dose escalation | Pharmacokinetics | CYP2D6 polymorphism | ALLELE | POPULATION | FREQUENCIES | GENETIC POLYMORPHISMS | PHARMACEUTICALS | CYTOCHROME-P450 2D6 GENOTYPE | CYP2D6-ASTERISK-10 | VARIABILITY | dose escalation | paroxetine | METABOLISM | pharmacokinetics | PHARMACOLOGY & PHARMACY | MAJOR DEPRESSIVE DISORDER | Paroxetine - pharmacokinetics | Cytochrome P-450 CYP2D6 - genetics | Serotonin Uptake Inhibitors - pharmacokinetics | Tablets | Area Under Curve | Humans | Male | Polymorphism, Genetic | Cross-Over Studies | Dose-Response Relationship, Drug | Paroxetine - administration & dosage | Young Adult | Tandem Mass Spectrometry | Asian Continental Ancestry Group | Serotonin Uptake Inhibitors - administration & dosage | Chromatography, Liquid | Adult | Female | Delayed-Action Preparations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Influence of the cytochrome P450 2D610/10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis
by Nishimura, M and Ueda, M and Saruwatari, J and Nakashima, H and Ogusu, N and Aoki, A and Tsuchimine, S and Matsuda, K and Iwashita, K and Ono, T and Oniki, K and Shimoda, K and Yasui-Furukori, N
PHARMACOGENETICS AND GENOMICS, ISSN 1744-6872, 09/2016, Volume 26, Issue 9, pp. 403 - 413
Objective Although the reduced function of the cytochrome P450 2D6*10 (CYP2D6*10) allele is common among Asian populations, existing evidence does not support... 
ALLELE | ACTIVITY SCORE | polymorphisms | dose requirement | population pharmacokinetics | IMPACT | paroxetine | MECHANISM-BASED INHIBITION | CYP2D6 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | GENES | GENETICS & HEREDITY | PHARMACOLOGY & PHARMACY | PLASMA-CONCENTRATION
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin
by Chen, Grace and Zhang, Wencan and Serenko, Michael
The Journal of Clinical Pharmacology, ISSN 0091-2700, 06/2015, Volume 55, Issue 6, pp. 671 - 679
Vortioxetine is an antidepressant with multimodal activity approved for the treatment of major depressive disorder. Two separate randomized, placebo‐controlled... 
pharmacokinetics | platelet | bleeding | coagulation | vortioxetine | drug‐drug interaction | Platelet | Drug-drug interaction | Pharmacokinetics | Vortioxetine | Bleeding | Coagulation | drug-drug interaction | ANTIDEPRESSANT | RISK | MULTIMODAL COMPOUND | SEROTONIN REUPTAKE INHIBITORS | IN-VITRO | THERAPY | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | PAROXETINE | PHARMACOLOGY & PHARMACY | MAJOR DEPRESSIVE DISORDER | LU AA21004 | Piperazines - administration & dosage | Anticoagulants - administration & dosage | Area Under Curve | Humans | Middle Aged | Aspirin - pharmacokinetics | Male | Healthy Volunteers | Warfarin - administration & dosage | Sulfides - administration & dosage | Aspirin - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Sulfides - pharmacokinetics | Drug Interactions | Adult | Female | Platelet Aggregation - drug effects | Piperazines - pharmacokinetics | Warfarin - pharmacokinetics | Cross-Over Studies | International Normalized Ratio | Blood Coagulation - drug effects | Adolescent | Antidepressive Agents - administration & dosage | Anticoagulants - pharmacokinetics | Antidepressive Agents - pharmacokinetics | Physiological aspects | Aspirin | Warfarin | Dosage and administration | Observations | Drug interactions | Preventive medicine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice
by Stasiuk, Weronika and Stasiuk, Weronika and Szopa, Aleksandra and Szopa, Aleksandra and Serefko, Anna and Serefko, Anna and Wyska, Elżbieta and Wyska, Elżbieta and Świąder, Katarzyna and Świąder, Katarzyna and Dudka, Jarosław and Dudka, Jarosław and Wlaź, Piotr and Wlaź, Piotr and Poleszak, Ewa and Poleszak, Ewa
Journal of Neural Transmission, ISSN 0300-9564, 3/2017, Volume 124, Issue 3, pp. 387 - 396
Pre-clinical and clinical studies indicated that a blockade of the NMDA receptor complex creates new opportunities for the treatment of affective disorders,... 
Neurology | Neurosciences | Traxoprodil | Forced swim test | Pharmacokinetic study | Medicine & Public Health | Antidepressants | NMDA receptor ligand | Mice | Pharmacology/Toxicology | Psychiatry | TAIL SUSPENSION TEST | INVOLVEMENT | RATS | D-ASPARTATE ANTAGONIST | ZINC SUPPLEMENTATION | NEUROSCIENCES | CLINICAL NEUROLOGY | AMPA RECEPTORS | CP-101,606 | DRUGS | MAJOR DEPRESSIVE DISORDER | Paroxetine - pharmacokinetics | Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors | Excitatory Amino Acid Antagonists - pharmacokinetics | Motor Activity - drug effects | Depressive Disorder - drug therapy | Male | Chromatography, High Pressure Liquid | Brain - metabolism | Desipramine - pharmacology | Drug Interactions | Piperidines - pharmacology | Piperidines - pharmacokinetics | Antidepressive Agents - pharmacology | Cyclopropanes - pharmacokinetics | Cyclopropanes - pharmacology | Disease Models, Animal | Bupropion - pharmacokinetics | Injections, Intraperitoneal | Excitatory Amino Acid Antagonists - pharmacology | Depressive Disorder - metabolism | Brain - drug effects | Desipramine - pharmacokinetics | Animals | Analysis of Variance | Bupropion - pharmacology | Antidepressive Agents - pharmacokinetics | Paroxetine - pharmacology | Physiological aspects | Paroxetine | Depression, Mental | Index Medicus | Psychiatry and Preclinical Psychiatric Studies - Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Single- and multiple-dose pharmacokinetics and tolerability of a paroxetine controlled-release tablet in healthy Chinese subjects
by Chen, R and Shen, K and Hu, P
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, ISSN 0946-1965, 03/2017, Volume 55, Issue 3, pp. 231 - 236
Objectives: To evaluate the pharmacokinetics of paroxetine controlled-release (CR) tablets after single and multiple oral administrations and to evaluate its... 
DEPRESSION | INHIBITION | PHARMACEUTICALS | EFFICACY | CYTOCHROME-P450 ENZYMES | paroxetine controlled-release | tolerability | pharmacokinetics | PHARMACOLOGY & PHARMACY | INDUCTION | Paroxetine - pharmacokinetics | Antidepressive Agents, Second-Generation - adverse effects | Antidepressive Agents, Second-Generation - pharmacokinetics | Serotonin Uptake Inhibitors - pharmacokinetics | Tablets | Area Under Curve | Humans | Half-Life | Male | Metabolic Clearance Rate | Antidepressive Agents, Second-Generation - administration & dosage | Healthy Volunteers | Antidepressive Agents, Second-Generation - blood | Paroxetine - adverse effects | Paroxetine - administration & dosage | Young Adult | Paroxetine - blood | Tandem Mass Spectrometry | Chromatography, Liquid | Adult | Female | Serotonin Uptake Inhibitors - blood | Drug Administration Schedule | Administration, Oral | Serotonin Uptake Inhibitors - adverse effects | Asian Continental Ancestry Group | Serotonin Uptake Inhibitors - administration & dosage | Models, Biological | Delayed-Action Preparations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Single‐ and Multiple‐Dose Pharmacokinetics of Dapoxetine Hydrochloride, a Novel Agent for the Treatment of Premature Ejaculation
by Modi, Nishit B and Dresser, Mark J and Simon, Mary and Lin, Denise and Desai, Dhaval and Gupta, Suneel
The Journal of Clinical Pharmacology, ISSN 0091-2700, 03/2006, Volume 46, Issue 3, pp. 301 - 309
Dapoxetine is a serotonin transporter inhibitor currently in development for the treatment of premature ejaculation. This randomized, 2‐sequence, 2‐treatment... 
pharmacokinetics | premature ejaculation | Dapoxetine | Premature ejaculation | Pharmacokinetics | ANTIDEPRESSANTS | dapoxetine | SERTRALINE | FLUVOXAMINE | DOUBLE-BLIND | PAROXETINE | PHARMACOLOGY & PHARMACY | SEXUAL DYSFUNCTION | FLUOXETINE | Serotonin Uptake Inhibitors - metabolism | Serotonin Uptake Inhibitors - pharmacokinetics | Drug Administration Schedule | Administration, Oral | Humans | Middle Aged | Sexual Dysfunction, Physiological - drug therapy | Male | Naphthalenes - blood | Benzylamines - administration & dosage | Benzylamines - metabolism | Cross-Over Studies | Dose-Response Relationship, Drug | Serotonin Uptake Inhibitors - administration & dosage | Naphthalenes - administration & dosage | Adolescent | Adult | Serotonin Uptake Inhibitors - blood | Naphthalenes - pharmacokinetics | Benzylamines - pharmacokinetics | Ejaculation - drug effects | Benzylamines - blood | Drug Monitoring | Naphthalenes - metabolism | Care and treatment | Research | Serotonin agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11C]DASB Positron Emission Tomography Study
by Meyer, Jeffrey H and Wilson, Alan A and Sagrati, Sandra and Hussey, Doug and Carella, Anna and Potter, William Z and Ginovart, Nathalie and Spencer, Edgar P and Cheok, Andy and Houle, Sylvain
American Journal of Psychiatry, ISSN 0002-953X, 05/2004, Volume 161, Issue 5, pp. 826 - 835
OBJECTIVE: Minimum therapeutic doses of paroxetine and citalopram produce 80% occupancy for the serotonin (5-HT) transporter (5-HTT). The authors used... 
H-3 PAROXETINE BINDING | ANTIDEPRESSANTS | DASB | 5-HT2 RECEPTORS | PSYCHIATRY | IN-VIVO | HIGH-AFFINITY | HUMAN-BRAIN | MAJOR DEPRESSION | UPTAKE SITES | PET | Paroxetine - pharmacokinetics | Serotonin Uptake Inhibitors - pharmacokinetics | Cyclohexanols - pharmacokinetics | Fluoxetine - pharmacokinetics | Membrane Glycoproteins - metabolism | Humans | Middle Aged | Male | Paroxetine - therapeutic use | Serotonin Plasma Membrane Transport Proteins | Carrier Proteins - drug effects | Corpus Striatum - metabolism | Dose-Response Relationship, Drug | Sertraline - pharmacokinetics | Sertraline - therapeutic use | Adult | Female | Fluoxetine - therapeutic use | Serotonin Uptake Inhibitors - therapeutic use | Nerve Tissue Proteins | Venlafaxine Hydrochloride | Carrier Proteins - metabolism | Membrane Transport Proteins | Serotonin - metabolism | Benzylamines | Corpus Striatum - drug effects | Cyclohexanols - therapeutic use | Membrane Glycoproteins - drug effects | Citalopram - pharmacokinetics | Citalopram - therapeutic use | Tomography, Emission-Computed | Corpus Striatum - diagnostic imaging | Delayed-Action Preparations | Carbon Radioisotopes | Dosage and administration | Serotonin agents | Drug therapy | Mental illness
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine
by Nassan, Malik, MBBS and Nicholson, Wayne T., MD, PharmD and Elliott, Michelle A., MD and Rohrer Vitek, Carolyn R., MS and Black, John L., MD and Frye, Mark A., MD
Mayo Clinic Proceedings, ISSN 0025-6196, 2016, Volume 91, Issue 7, pp. 897 - 907
Abstract Antidepressants are commonly prescribed medications in the United States, and there is increasing interest in individualizing treatment selection for... 
Internal Medicine | CLINICAL IMPROVEMENT | CYP2C19 GENOTYPES | SEROTONIN REUPTAKE INHIBITORS | GENETIC-VARIATION | MEDICINE, GENERAL & INTERNAL | PLASMA-CONCENTRATIONS | CYTOCHROME-P450 2D6 GENOTYPE | DOSE-RESPONSE RELATIONSHIP | TRANSPORTER OCCUPANCY | MAJOR DEPRESSIVE DISORDER | DRUG CONCENTRATION | Paroxetine - pharmacokinetics | Antidepressive Agents, Second-Generation - adverse effects | Antidepressive Agents, Second-Generation - pharmacokinetics | Cytochrome P-450 Enzyme Inhibitors - therapeutic use | Fluoxetine - pharmacokinetics | Precision Medicine - standards | Humans | Cytochrome P-450 Enzyme Inhibitors - adverse effects | Paroxetine - therapeutic use | Venlafaxine Hydrochloride - therapeutic use | Antidepressive Agents, Second-Generation - therapeutic use | Venlafaxine Hydrochloride - adverse effects | Paroxetine - adverse effects | Fluoxetine - therapeutic use | Fluoxetine - adverse effects | Pharmacogenetics - standards | Depressive Disorder, Major - drug therapy | Cytochrome P-450 CYP2D6 - genetics | Pharmacogenetics - methods | Prescription Drugs - standards | Cytochrome P-450 Enzyme Inhibitors - pharmacokinetics | Depressive Disorder, Major - genetics | Venlafaxine Hydrochloride - pharmacokinetics | Precision Medicine - methods | Practice Guidelines as Topic | Genetic variation | Patient outcomes | Dosage and administration | Genetic aspects | Research | Drug therapy | Genetic screening | Major depressive disorder | Antidepressants, Tricyclic | Drugs | Prescription writing | Drug approval
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. INFLUENCE OF FLUVOXAMINE ON CARVEDILOL'S PHARMACOKINETICS IN RATS
by Abrudan, MB and Muntean, DM and Vlase, L and Gheldiu, AM and Berce, C and Stoicescu, L and Neag, MA
FARMACIA, ISSN 0014-8237, 07/2019, Volume 67, Issue 4, pp. 616 - 620
Carvedilol is one of the most used cardiovascular drugs, highly metabolized by CYP450 2D6, 1A2, 2C9. Fluvoxamine, an antidepressant agent, is a moderate/potent... 
CITALOPRAM | inhibition | NEBIVOLOL | cytochrome P450 | FLUOXETINE | ZOLPIDEM | METABOLISM | CYP2D6 | BUPROPION | Carvedilol | PAROXETINE | PHARMACOLOGY & PHARMACY | STEADY-STATE
Journal Article
Details down arrow
16. Full Text Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone
by Kummer, Oliver and Kummer, Oliver and Hammann, Felix and Hammann, Felix and Moser, Claudine and Moser, Claudine and Schaller, Olivier and Schaller, Olivier and Drewe, Jürgen and Drewe, Jürgen and Krähenbühl, Stephan and Krähenbühl, Stephan
European Journal of Clinical Pharmacology, ISSN 0031-6970, 1/2011, Volume 67, Issue 1, pp. 63 - 71
The main metabolic pathways of oxycodone, a potent opioid analgetic, are N-demethylation (CYP3A4) to inactive noroxycodone and O-demethylation (CYP2D6) to... 
Paroxetine | Pharmacodynamics | Biomedicine | Ketoconazole | Oxycodone | Drug interactions | Pharmacology/Toxicology | Pharmacokinetics | MORPHINE | CONTROLLED-RELEASE OXYCODONE | FLUOXETINE | N-DEALKYLATION | SEROTONIN REUPTAKE INHIBITOR | DOUBLE-BLIND